PubMed
Cagrilintide, a long-acting amylin analogue, for the treatment of obesity
Lau DCW, Erondu N, Skovgaard D, et al. Lancet. 2022
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 53% · Mixed 28% · Unfavorable overall 19%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.6–1 mg · Most common: 0.6–1 mg
Reports span 0.05 to ≥ 5 mg (open-ended top bucket)
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 63% said they felt similar to their last entry, 39% more positive, and 13% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 25 days · Based on 343 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 60% · Mixed 32% · Unfavorable overall 8%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 100–200 mcg · Most common: 100–200 mcg
Reports span 0–1000 mcg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 14 days · Based on 312 repeat reporters
Published sources linked on the Cagrilintide and CBL-514 wiki pages.
PubMed
Lau DCW, Erondu N, Skovgaard D, et al. Lancet. 2022
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
D'Ascanio AM, Mullally JA, Frishman WH. Cardiology in review. 2024
PubMed
Garvey WT, Blüher M, Osorto Contreras CK, et al. The New England journal of medicine. 2025
PubMed
Gold M, Schlessinger J, Goodman GJ, et al. Aesthetic Surgery Journal. 2025
PubMed
Lorenc ZP, Gold M, Schlessinger J, et al. Aesthetic Surgery Journal. 2026
PubMed
Goodman GJ, Ho WWS, Chang KJ, et al. Aesthetic Surgery Journal. 2022
PubMed
Herbst KL, Ling YF, Sheu AY, et al. JAAD International. 2026
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2026
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2026
Manufacturer
Caliway Biopharmaceuticals. Company press release. 2026
Manufacturer
Caliway Biopharmaceuticals. Company press release. 2026
Manufacturer
Caliway Biopharmaceuticals. Company press release. 2026
FDA Drug Label
Allergan. FDA Drug Label. 2015
Review Article
Tina Hesman Saey, Science News. Science News. 2026
Review Article
News-Medical.net. Conference news summary. 2026